Literature DB >> 30515664

FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders.

Alexandra Doncarli1, Virginie Demiguel2, Irina Guseva Canu2,3, Véronique Goulet2, Sophie Bayart4, Thierry Calvez5, Sabine Castet6, Vincent Dalibard7, Yohan Demay8, Birgit Frotscher9, Jenny Goudemand10, Thierry Lambert11, Vanessa Milien12, Caroline Oudot13, Thomas Sannié14, Hervé Chambost15.   

Abstract

FranceCoag is an ongoing open prospective multicentre cohort project aimed at improving epidemiological knowledge about inherited bleeding disorders in France. The main objective of this article was to evaluate the project's progress as of the 30th December 2016. Between 1994 and this date, of the 10,047 patients included in the study, 384 (3.8%) were reported by clinicians to have died and 159 (1.6%) to be lost to follow-up. Among the remaining 9504 patients still being followed up, 5748 (60.5%) had haemophilia A, 1300 (13.7%) haemophilia B, 1980 (20.8%) von Willebrand Disease while 476 (5.0%) had another clotting factor deficiency (Factor I, II, V, combined V and VIII, VII, X, XI and XIII). The median age of the population was 32 years (Inter-quartile range (IQR) 18-50 years) at data extraction on December 30th, 2016. The subgroup of children (i.e., < 18 years old) with severe haemophilia and comprehensive information available since the first exposure to treatment was identified as the PUPs (Previously Untreated Patients) cohort. Data for the 643 children included in the PUPs' cohort had been collected since their birth. Follow-up data were collected by the clinicians in haemophilia treatment centres (HTC) every 12.9 months on median (IQR 11.4-21.3). In the PUPS cohort, data were updated every 6.2 months on median (IQR 3.7-11.7). A unique patient number assigned at study inclusion was kept at individual HTC by participating clinicians. The data collected included demographic, clinical, therapeutic and biological items on standard electronic forms. As of December 30th 2016, a plasma and serum samples was available for 2581 patients (27.1%).

Entities:  

Keywords:  Haemophilia; Inhibitor; Prophylaxis; Rare inherited disease; Risk factor

Mesh:

Year:  2018        PMID: 30515664     DOI: 10.1007/s10654-018-0468-7

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  11 in total

1.  [Epidemiology of hereditary bleeding disorders: input of FranceCoag Network].

Authors:  H Chambost; F Suzan
Journal:  Arch Pediatr       Date:  2010-06       Impact factor: 1.180

2.  Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Authors:  Thierry Calvez; Hervé Chambost; Ségolène Claeyssens-Donadel; Roseline d'Oiron; Véronique Goulet; Benoît Guillet; Virginie Héritier; Vanessa Milien; Chantal Rothschild; Valérie Roussel-Robert; Christine Vinciguerra; Jenny Goudemand
Journal:  Blood       Date:  2014-09-24       Impact factor: 22.113

3.  Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.

Authors:  Valérie Gaboulaud; Armelle Parquet; Cedric Tahiri; Ségolène Claeyssens; Valérie Potard; Albert Faradji; Jocelyne Peynet; Dominique Costagliola
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

4.  Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

Authors:  Peter W Collins; Benedict P Palmer; Elizabeth A Chalmers; Daniel P Hart; Ri Liesner; Savita Rangarajan; Katherine Talks; Michael Williams; Charles R M Hay
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

5.  The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system.

Authors:  T Calvez; M Biou; D Costagliola; A M Jullien; Y Laurian; F Rossi; C Rothschild; P Sié
Journal:  Haemophilia       Date:  2001-01       Impact factor: 4.287

6.  What factors influence the age at diagnosis of hemophilia? Results of the French hemophilia cohort.

Authors:  Hervé Chambost; Valérie Gaboulaud; Brigitte Coatmélec; Anne Rafowicz; P Schneider; Thierry Calvez
Journal:  J Pediatr       Date:  2002-10       Impact factor: 4.406

7.  Factor VIII products and inhibitor development in severe hemophilia A.

Authors:  Samantha C Gouw; Johanna G van der Bom; Rolf Ljung; Carmen Escuriola; Ana R Cid; Ségolène Claeyssens-Donadel; Christel van Geet; Gili Kenet; Anne Mäkipernaa; Angelo Claudio Molinari; Wolfgang Muntean; Rainer Kobelt; George Rivard; Elena Santagostino; Angela Thomas; H Marijke van den Berg
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

8.  Use of clinical practice guidelines on long-term prophylaxis in severe hemophilia in France: a retrospective audit.

Authors:  Sandrine Meunier; Hervé Chambost; Virginie Demiguel; Alexandra Doncarli; Florence Suzan; Marc Trossaërt
Journal:  J Pediatr       Date:  2013-01-17       Impact factor: 4.406

9.  A study of variations in the reported haemophilia A prevalence around the world.

Authors:  J S Stonebraker; P H B Bolton-Maggs; J Michael Soucie; I Walker; M Brooker
Journal:  Haemophilia       Date:  2009-10-21       Impact factor: 4.287

10.  CEMARA: a Web dynamic application within a N-tier architecture for rare diseases.

Authors:  Claude Messiaen; Loïc Le Mignot; Ana Rath; Jean-Baptiste Richard; Eric Dufour; Mohamed Ben Said; Jean-Philippe Jais; Alain Verloes; Martine Le Merrer; Christine Bodemer; Geneviève Baujat; Marion Gerard-Blanluet; Eva Bourdon-Lanoy; Rémi Salomon; Ségolène Ayme; Paul Landais
Journal:  Stud Health Technol Inform       Date:  2008
View more
  3 in total

1.  Objectives, design and main findings until 2020 from the Rotterdam Study.

Authors:  M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman
Journal:  Eur J Epidemiol       Date:  2020-05-04       Impact factor: 8.082

2.  Effectiveness of long-term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease.

Authors:  Lucia Rugeri; Annie Harroche; Yohan Repessé; Dominique Desprez; Brigitte Pan Petesch; Pierre Chamouni; Christine Biron; Birgit Frotscher; Hasan Catovic; Diane Bracquart; Cédric Martin; Marc Trossaërt; Sandrine Meunier; Roseline d'Oiron
Journal:  Eur J Haematol       Date:  2022-04-29       Impact factor: 3.674

3.  Haemophilia in France: Modelisation of the Clinical Pathway for Patients.

Authors:  Karen Beny; Benjamin du Sartz de Vigneulles; Florence Carrouel; Denis Bourgeois; Valérie Gay; Claude Negrier; Claude Dussart
Journal:  Int J Environ Res Public Health       Date:  2022-01-06       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.